Quantcast

US Drug Watchdog Now Urges Family Members Of Diabetics Who Have Been Diagnosed With Bladder Cancer To Ask If They Were Using the Diabetes Drug Called Actos

January 13, 2012

The US Drug Watchdog says, “We do not think the average bladder cancer victim, who is also a diabetic would ever consider a drug for diabetes could be a contributing factor for bladder cancer, so we are urging loved ones, or family members to ask the question-were you using Actos before being diagnosed with bladder cancer? There may be a elevated incidence of bladder cancer for users of the diabetes drug called Actos, and we want to identify every US victim, in the hopes we can get them some meaningful help, and get them to the best possible law firms. ” According to the AP, “The FDA has issued a warning that Actos may be linked to an increased risk of bladder cancer. Meanwhile, both Germany and France have suspended sales of Actos. The Actos suspension is effective July 11, 2011. Actos (pioglitazone), along with another diabetes drug made by Takeda Pharmaceutical, Competact, came under fire in Europe after a study revealed an increased risk for bladder cancer among diabetes patients who were taking the medication.” The US Drug Watchdog says, “We want to hear from any user of the diabetes medication called Actos, if they have developed bladder cancer. If after using Actos you, or a loved one developed bladder cancer please call our group immediately at 866-714-6466.” http://USDrugWatchdog.Com

(PRWEB) January 13, 2012

The US Drug Watchdog says, “No one would ever consider the possibility of a drug used for diabetes could also be related to elevated cases of bladder cancer. Unfortunately, the use of Actos for diabetes, and an elevated chance of bladder cancer could to be related. We need the help of loved ones, or family members of diabetics, who now have bladder cancer, to ask if the diabetic was using, or has also used the drug called Actos. There appears to be a correlation between US diabetics, bladder cancer, and the drug called Actos, and we want to identify every possible victim.” Actos is a member of a class of drugs known as thiazolidinediones, which have been linked to bladder cancer. Actos side effects include increased risk of congestive heart failure, and an increased risk for bladder cancer. According to the AP, “The US FDA has also issued a warning about Actos, and bladder cancer. Both Germany and France have suspended sales of Actos. The Actos suspension is effective July 11, 2011. Actos (pioglitazone), along with another diabetes drug made by Takeda Pharmaceutical, Competact, came under fire in Europe after a study revealed an increased risk for bladder cancer among diabetes patients who were taking the medication.” The US Drug Watchdog says, “We want to identify any user of the diabetes drug called Actos, if they have developed bladder cancer, and we think we will need the help of family members, and loved ones to get these victims identified.” For more information please call the US Drug Watchdog anytime at 866-714-6466, or contact the group via their web site at http://USDrugWatchdog.Com

The US Drug Watchdog is the premier private pharmaceutical watchdog in the United States. The group says, “Tragically the Internet is loaded with misleading ads about Actos use, and bladder cancer compensation, lawsuits, or class actions. Unfortunately, most of the attorneys or law firms advertising for help with the diabetes drug called Actos, and bladder cancer are middlemen marketing law firms–not the actual trial law firms that will prosecute these cases.” They say, “We want to make certain all Actos bladder cancer victims get to the actual trial law firms or attorneys that have the best record in achieving superior results for their clients–period–no middleman marketing law firms, or attorneys.” For more information please contact the US Drug Watchdog anytime at 866-714-6466, or contact the group via its web site at http://USDrugWatchdog.com

Case number 11cv2406 BEN BGS in the Federal District Court San Diego, CA.

###

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/1/prweb9100585.htm


Source: prweb



comments powered by Disqus